Acute myelogenous leukemia : genetics, biology and therapy /

Acute myelogenous leukemia (AML), is the most common form of leukemia in adults. AML is a deadly form of malignancy, the prognosis for which has not improved in the last two decades. More importantly, it is a malignancy that is seen in older adults, therefore the number of cases is likely to rise as...

Full description

Bibliographic Details
Main Author: Alatrash, Gheath (Autor/a)
Other Authors: Andreeff, Michael 1943- (Autor/a), Borthakur, Gautam (Autor/a), Calín, George A. (Autor/a), Carter, Bing (Autor/a), Nagarajan, Lalitha (Editor/a)
Format: Book
Language:English
Published: New York : Springer, [2010].
Series:Cancer treatment and research / series editor Steven T. Rosen, Robert H. Lurie
Subjects:
Online Access:Ver documento en línea
LEADER 02397nam a2200385 a 4500
001 000648062
005 20250731152918.0
008 210803s2010 nyuad gs ||||||eng d
020 |a 9780387692593  |q (ebook) 
020 |a 9780387692579 
040 |a Sistema de Bibliotecas del Universidad de Costa Rica 
082 0 |a 616.994.19  |2 23 
100 1 |a Alatrash, Gheath  |e Autor/a 
245 1 0 |a Acute myelogenous leukemia :  |b genetics, biology and therapy /  |c Lalitha Nagarajan, editor ; contributors, Gheath Alatrash, Michael Andreeff, Gautam Borthakur, George A. Calin, Bing Carter [y otros veintiseis]. 
264 1 |a New York :  |b Springer,  |c [2010]. 
264 4 |c ©2010 
300 |a 1 recurso en línea (ix, 280 páginas) :  |b ilustraciones (principalmente a color), diagrama a color, archivo de texto, PDF. 
490 0 |a Cancer treatment and research / series editor Steven T. Rosen, Robert H. Lurie 
500 |a La función de los autores fue determinada por el catalogador 
506 |a Acceso al texto completo para la comunidad de la UCR por medio de la cuenta institucional 
520 3 |a Acute myelogenous leukemia (AML), is the most common form of leukemia in adults. AML is a deadly form of malignancy, the prognosis for which has not improved in the last two decades. More importantly, it is a malignancy that is seen in older adults, therefore the number of cases is likely to rise as the population ages. Over the past 15 years, genetic mechanisms underlying AML have begun to unfold. Additional research in this area has helped identify key components and characteristics. Consequently, targeted therapy of AML is receiving much attention. It is the hope of researchers that as with chronic myelogenous leukemia (CML), and the drug, Gleevec, a targeted therapy for AML will be discovered. 
650 0 7 |a LEUCEMIA MIELOCITICA AGUDA 
650 0 7 |a LEUCEMIA  |x GENÉTICA 
650 0 7 |a LEUCEMIA  |x FISIOPATOLOGÍA 
650 0 7 |a LEUCEMIA  |x TRATAMIENTO 
650 0 7 |a BIOLOGIA MOLECULAR 
700 1 |a Andreeff, Michael  |d 1943-  |e Autor/a 
700 1 |a Borthakur, Gautam  |e Autor/a 
700 1 |a Calín, George A.  |e Autor/a 
700 1 |a Carter, Bing  |e Autor/a 
700 1 |a Nagarajan, Lalitha  |e Editor/a 
856 4 1 |u https://springerlink.proxyucr.elogim.com/book/10.1007/978-0-387-69259-3  |y Ver documento en línea 
900 |a 2025-O 
916 |a Centro Catalográfico 
949 |a ACC -KAF